![](https://i.imgur.com/CLvY2jA.png")
11-08-2021, 10:58 AM
Some current messenger ribonucleic acid (mRNA) vaccines have lower effectiveness in protecting against symptomatic disease when it comes to targeting certain variants. Prof Low said a booster jab may be needed for these vaccines in future as the virus will continue to circulate.
Prof Low, the unit's deputy clinical and scientific director, told The Straits Times: "The two new vaccines, ARCT-154 and ARCT-165 will be tested together with the original ARCT-021 vaccine, where we will compare all three vaccines against one another for their safety and antibody protection."
The ARCT-021 vaccine, which was previously known as the Lunar-Cov19 vaccine, is still undergoing phase two of its clinical trials, which began earlier this year. It was co-developed by Duke-NUS and Arcturus Therapeutics, and targets the original or wild-type Sars-CoV-2 virus.
https://www.straitstimes.com/singapore/h...rget-delta
Prof Low, the unit's deputy clinical and scientific director, told The Straits Times: "The two new vaccines, ARCT-154 and ARCT-165 will be tested together with the original ARCT-021 vaccine, where we will compare all three vaccines against one another for their safety and antibody protection."
The ARCT-021 vaccine, which was previously known as the Lunar-Cov19 vaccine, is still undergoing phase two of its clinical trials, which began earlier this year. It was co-developed by Duke-NUS and Arcturus Therapeutics, and targets the original or wild-type Sars-CoV-2 virus.
https://www.straitstimes.com/singapore/h...rget-delta
